by Barry101 | Jul 3, 2024 | Press Release
OCALA, Fla., July 03, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, AIM Chief Executive...
by Barry101 | Jun 10, 2024 | Press Release
Live video webcast on Monday, June 17th at 1:00 PM ETOCALA, Fla., June 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...
by Barry101 | Jun 3, 2024 | Press Release
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ETOCALA, Fla., June 03, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that...
by Barry101 | May 31, 2024 | Press Release
OCALA, Fla., May 31, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of...
by Barry101 | May 20, 2024 | Press Release
OCALA, Fla., May 20, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences. Details for the...
by Barry101 | May 16, 2024 | Press Release
Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 — AIM ImmunoTech Inc....
